Introduction
A number of plant-derived agents are currently successfully used in cancer treatment, such as vinca alkaloid, etoposide, taxanes paclitaxel, etc., whereas some are currently under investigation [1] . Berberine ( Fig. 1) , an isoquinoline alkaloid, belongs to the structural class of protoberberines. It is present in the roots, rhizome, and stem bark of a number of important medicinal plant species including Berberis vulgaris (barberry), Hydrastis canadensis (goldenseal) (Ranunculaceae), Coptis chinensis (Coptis or goldenthread) (Ranunculaceae), Arcangelisia flava (Menispermaceae), B. aquifolium (Oregon grape), and B. aristata (tree turmeric) [2] . Coptis chinensis (Rhizoma coptidis) and Baical Skullcap Root (Radix scutellariae), which contain a large amount of berberine and other protoberberines, have been widely prescribed by traditional Chinese physicians as heat-clearing and detoxicating medicine for thousands of years. Since the last century, berberine has been extensively investigated and was found to possess a wide variety of pharmacological and biological activities, such as antimicrobial, antihelmintic, anti-inflammatory, and anti-oxidative effects [3] [4] [5] . Recently, many researchers have been particularly interested in the antineoplastic activities of berberine and have obtained some promising and interesting results both in vitro and in vivo, which will be discussed in detail in this review.
The anticancer activity of berberine Inhibition of tumorigenic microorganisms
The strong antimicrobial activities of extracts from Rhizoma coptidis and Radix scutellariae, two important sources of berberine in nature, have been firmly established by inhibiting the growth of Klebsiella pneumoniae, Proteus vulgaris, Mycobacterium smegmatis, Candida albicans [6] , Heliobacter pylori [7] , and the intestinal protozoan parasite Blastocystis hominis in vitro [8] . Further studies have shown that this antimicrobial effect was mainly because of one of the active compounds in these herbs, berberine, which displayed significant antibacterial and antifungal activities against Staphylococcus aureus and different Candida spp., Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, and Leishmania donovani [2] . Berberine inhibits the growth of Helicobacter pylori in vitro with a minimum inhibitory concentration at 12.5 mg/ml [9] . In hepatitis B virus permanently transfected HepG2 2.2.15 cells, berberine not only markedly reduces viral production, but also induces toxicity in host cells [10] , but does not show inhibitory activity against HbsAg and HbeAg [11] . In view of the etiological close relationship between the pathogenic microorganism and tumorigenesis, such as the discovery of the bacterium Helicobacter pylori as the main etiologic organism of chronic gastritis, peptic ulcer disease, and gastric cancer [12, 13] , the antimicrobial activity of berberine might contribute to its anticancer potential.
Regulation of oncogene and carcinogenesis-related gene expression
Some human teratocarcinoma cell lines and tumor tissues exhibit amplification and enhanced expression of c-Ki-ras2 protooncogene [14] . Berberine treatment induced a pluripotent human teratocarcinoma cell clone NT2/D1, which was derived from the Tera-2 cell line, to differentiate into cells with neuronal cell morphology. This effect was absent in murine teratocarcinoma cell line, F9 [15] and might be because of its downregulation of c-Ki-ras2 gene mRNA expression [16] . More recently, it was discovered that berberine could increase the activity of AMP-activated protein kinase, which lead to phosphorylation activation of the tumor suppressor gene p53 in vascular smooth muscle cells (VSMCs) [17] . Furthermore, a very new study revealed that p53 showed a cooperative effect on berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo [18] .
The cellular signaling cascades mediated by transcription factors, including nuclear factor E2-related factor 2 (Nrf2), nuclear factor-kB (NF-kB), and activator protein-1 (AP-1), have been shown to play pivotal roles in tumor initiation, promotion, and progression processes [19] . A reporter gene assay showed that berberine exhibited an inhibitory effect on AP-1 activity in a dosedependent and time-dependent manner in human hepatoma cells [20] . However, another study suggested that berberine had no effect on AP-1 activity under the conditions it suppresses NF-kB in Jurkat cells [21] . This inconsistence might be because of the cell difference, but is more likely to result from the incubation time, as the former study showed that berberine inhibited AP-1 activity almost completely at a concentration as low as 10 mmol/l after 48 h treatment, whereas in the latter study the cells were treated with berberine only for 30 min [20, 21] . This interpretation was further supported by another study, which showed that berberine inhibited constitutively expressed and TPA-induced binding of AP-1 in human oral epidermal carcinoma cell, KB, and oral squamous cell carcinoma cell, OC2, after 2 h treatment [5] . These results suggested that berberine exhibited pharmacological effects in a slow and smooth manner at lower concentrations (r 25 mmol/l), which was also observed in its apoptosis-promoting and antiproliferative effects in human epidermoid carcinoma cells, A431, U937cells, B16 cells, HL-60 cells, etc. [22] [23] [24] . In fact, as will be discussed below, berberine showed high affinity to both DNA and RNA. Hence, its integration with DNA in nuclear material might consequently hinder AP-1 binding.
Interaction with DNA and RNA
The interaction between berberine and DNA or RNA to form a berberine-DNA complex or a berberine-RNA complex might be one of its anticancer mechanisms. Earlier studies have shown that a single berberine molecule binds to DNA to form a complex with DNA [25] in a pH-dependent manner [26] . Furthermore, it showed the greatest affinity for polyadenylic acid [poly(A)] and did not seem to associate significantly with polycytidylic acid [poly(C)] or polyuridylic acid [poly(U)] [27] . It is estimated that berberine binds strongly with polyguanylic acid and polyinosinic acid with an affinity in the order 10 -5 mol/l, whereas its binding to poly(C) and poly(U) is very weak or practically nil [28] . This characteristic was once used to stain DNA and RNA in earlier studies, as berberine is a fluorescent compound with absorbance peaks at 230, 267, 344, 420 nm, and peak emission at 550 nm [29] . Recently, the binding of berberine with DNA and RNA, and its binding affinities have been extensively studied by using several novel analytical techniques, including absorption, fluorescence, nuclear magnetic resonance, and electrospray ionization mass spectrometries. Islam and Suresh Kumar [28] determined the binding affinity, energetics, and conformational aspects of the interaction of berberine to four single stranded polyribonucleotides, polyguanylic acid, polyinosinic acid, poly(C), and poly(U), by absorption, fluorescence, isothermal titration calorimetry, and circular dichroism spectroscopy. Xia et al. [30] studied the interaction of berberine with DNA and the competitive interactions of daunorubicin and berberine with DNA by alternating penalty trilinear decomposition algorithm combined with excitation-emission matrix fluorescence data. Bhadra et al. [31] examined the equilibrium binding of berberine to various DNAs and the energetics of the interaction, which showed that the binding of berberine to DNA is dependent on base pair heterogeneity in the DNA conformation. Islam et al. [32, 33] studied the interaction of berberine and palmatine with tRNAphe and compared with the binding of the classical DNA intercalator, ethidium, which showed that the binding of berberine and palmatine on the tRNA structure appears to be mostly by partial intercalation, whereas ethidium intercalates fully on the tRNA. Tian et al. [34] investigated the interaction of berberine with double-strand DNA (dsDNA) and singlestrand DNA in solution, dsDNA immobilized on a glassy carbon electrode. The binding of berberine with DNA, when analyzed in terms of the cooperative Hill model, yields the binding constant K a = 2.2( ± 0.2) Â 10 -4 mol/l, corresponding to the dissociation equilibrium constant K d = 4.6( ± 0.3) Â 10 -5 = mol/l. A recent study showed that treatment of osteosarcoma cells and normal osteoblasts with berberine resulted in DNA double-strand breaks, which in turn triggered the activation of p53 and the p53-dependent cellular responses, including cell cycle arrest and apoptosis [35] .
Inhibition of carcinogenesis-related enzymes

Inhibition of N-acetyltransferase
It is well established that exposure to environmental and occupational chemicals is an important cause of chemical carcinogenesis. The arylamines, which are metabolized by cytosolic arylamine N-acetyltransferase (NAT) using acetyl coenzyme A as an acetyl donor to form reactive carcinogenic metabolites, represent one of the critical documented classes of chemicals known to induce tumors in humans [36, 37] . The important role of NAT in drug detoxification and carcinogen activation makes it a potential drug target [38] . Recently, it was discovered that berberine could dose-dependently inhibit NAT activity in several tumor cells, such as human bladder tumor (carcinoma) cells (T24) [39] , human colon tumor (adenocarcinoma) cells [40] , HL-60 human promyelocytic leukemia cells [41] , human malignant astrocytoma (G9T/VGH) and brain glioblastoma multiform (GBM 8401) cells [42] , and mouse lymphocytic leukemia cells (L1210) [43] . In addition, the gene and protein expression of NAT was also inhibited by berberine in a dosedependent and time-dependent manner in vitro [42, 44] .
Inhibition of cyclooxygenase-2
Accumulated evidence suggests that cyclooxygenase-2 (COX-2) plays a key role in colon [43] , skin [45] , prostate [46] , liver [47] , and lung [48] tumorigenesis and is supposed to be a new potential target for multiple cancer therapy [47, 49, 50] . Potentially, compounds inhibiting COX-2 transcriptional activity have, therefore, a chemopreventive property against tumor formation. Berberine inhibits COX-2 transcriptional activity effectively in a dose-dependent and time-dependent manner in colon cancer cells [51] , oral cancer cell line OC2 and KB cells [5, 52] , breast cancer MCF-7 cells, but not in MDA-MB-231 cells [53] . Berberine dose-dependently reduced prostaglandin E 2 production, which was mediated by the direct inhibition of AP-1 binding leading to the transcriptional suppression of COX-2 and reduced COX-2 protein, but not enzyme activity [5] . The effect of berberine on COX-2 expression and activity was supposed to be the basis of its anti-inflammatory effects and involved in the berberine-induced apoptosis [52] . However, in a human Cayman COX inhibitor screening assay, berberine showed no inhibitory effect on either COX isoform activities [54] .
Inhibition of telomerase
Telomeres, the ends of linear chromosomes, preserve genome stability and cell viability by preventing aberrant recombination and degradation of DNA. One of the hallmarks of advanced malignancies is continuous cell growth, and this almost universally correlates with the reactivation of telomerase [55] . Therefore, telomerase is an attractive cancer therapeutic target, as it seems to be essentially required in all tumors for immortalization of a subset of cells, including cancer stem cells [56] .
In HL-60 cells and human nasopharyngeal carcinoma (NPC) CNE-2 cells, berberine dose and time dependently inhibited telomerase activity [24, 57] , which was not because of the presence of inhibitors of telomerase activity [24] . Berberine also suppressed Plasmodium falciparum telomerase activity in a dose-dependent manner over a range of 30-300 mmol/l indicating that telomerase might be a potential target for future malaria chemotherapy [58] . However, its inhibitory effect on human telomerase in normal cells and other tumor cells need further study to be fully elucidated.
Inhibition of topoisomerase
DNA topoisomerases (Tops) represent a unique class of nuclear enzymes that alter the topological state of DNA by breaking and rejoining the sugar-phosphate backbone bonds of DNA and adjust the topological states of the DNA helix. Topoisomerase I (TopI) is capable of altering the topology of DNA by transiently breaking one DNA strand [59] , whereas topoisomerase II (TopII) catalyzes the ATP-dependent relaxation of negative and positive supercoils, knotting, unknotting, catenation, and decatenation of DNA by passing the dsDNA helix through a transient double-stranded break and then resealing the strand break [60] . The anticancer activity exhibited by camptothecin, a quinoline-based alkaloid found in the barks, seeds, and leaves of the Chinese Camptotheca tree (Xi Shu), against a broad spectrum of solid tumors has highlighted the Tops as a pragmatic molecular target for anticancer drugs and stimulated the exploration of Top inhibitors from traditional natural products.
The citations of the effect of berberine on Tops activity in some earlier publications were misleading to some extent, as these researchers did not make a distinction between berberine and one of its metabolites, berberrubine [22, 61, 62] . The water extract of Coptis chinensis was found to have the ability to stabilize the cleavable complex with mammalian DNA TopI, which was because of two protoberberine alkaloids, epiberberine and groenlandicine, whereas the berberrubine accounted for TopIImediated DNA cleavage in vitro [63] . Coralyne and its analog 5,6-dihydrocoralyne, which have appreciable structural similarity to berberine, showed TopI and TopII inhibitory activities suggesting that berberine might have TopI and/or TopII poisons [59, 64] . Berberrubine, a protoberberine, induces DNA cleavage in a site-specific and concentration-dependent manner, which results from its specific poison to TopII in vitro by stabilizing TopII-DNA cleavable complexes [60] . Four protoberberine analogs showed potent TopI poisoning activities but exhibited markedly different efficiency with a mechanistic model in which both ligand-DNA and ligandenzyme interactions are important [65] . These differences in specificity and structure-activity to Tops were because of the structural rigidity associated with the ring system and the substituents [59, 65] . In addition, AMC5 cells were resistance to berberrubine, which is associated with decreased level of catalytically active TopIIa, suggesting that TopIIa was the cellular target of berberrubine in vivo [66] . In fact, to the best of our knowledge, only recently Kettmann et al. [62] proposed a structural model for the ternary berberine-DNA-TopI cleavable complex and Qin et al. [67] showed that berberine inhibits TopI by stabilization of the enzyme-mediated DNA cleavable complex, just as camptothecin does.
Suppression of tumor cell proliferation
The antiproliferation/cytotoxicity of berberine has been extensively studied in various cell lines and primarily cultured cells, including multiple tumor cell lines and normal cells (Table 1) . Summarizing and analyzing these results, several special characteristics are obvious: (i) berberine exhibits different antiproliferation effects on different cells. For example, the murine melanoma B16 cell line was more sensitive to berberine treatment than the human promonocytic U937 cells (the values were 75-119 times lower) [23] . Similarly, the murine leukemia L1210 cells growing in suspension were more sensitive to berberine (IC 100 values were 2.3-4.1 times lower) than the human cervical carcinoma HeLa cell line growing as a monolayer [96] . Furthermore, different antiproliferative effect was clear even in the same category of tumor cells. The proliferation of six types of human esophageal cancer ECC cell lines (YES-1 to YES-6) was inhibited by berberine in a dose-dependent manner, but with the IC 50 varied from 0.11 to 0.90 mg/ml after 72 h treatment [87] . A study showed the cell sensitivity to berberine in increasing order to be B16 < EAC < V79 < U937 < L1210 < NIH-3T3 < HeLa cells [69] .
(ii) Berberine seems to be more active in inhibiting tumor cell proliferation, but shows minor cytotoxicity to normal cells. Berberine significantly inhibits human liver cancer cell line HepG2 [83, 89, 94] proliferation with an IC 50 of less than 50 mmol/l, whereas has little or no effect on primarily cultured hepatocyte isolated from Sprague-Dawley rats even at a concentration as high as 1 mmol/l [84] . A similar phenomenon was also observed in human GBM cell lines (SF188, SF210, SF126, and U87MG) and the primary cultures of normal human glia cells [79] . However, this might also be because of the short incubation time (half an hour) in berberine-treated primarily cultured hepatocytes [84] , as, in primarily cultured VSMCs, berberine also showed an inhibitory effect in a dose-dependent manner [17, 75] . (iii) A different IC 50 value for the same cell type was reported from different labs (Table 1) , which might result from different culture conditions and detection methods.
(iv) The effect of berberine is relatively slow and gentle, which means it generally exerts significant effects after 24 h treatment. Therefore, most investigators extend the incubation time to 72 h or even longer. However, in S180 cells, berberine exerts a marked but short-lived inhibitory action on cell growth [27] . (v) Berberine also shows potent inhibitory action on some cell proliferation inducer-promoted proliferation. Berberine significantly suppresses growth factor, angiotensin II, and heparin binding epidermal growth factor-induced VSMCs proliferation and migration in vitro by delaying or suppressing activation of Akt pathway [75] , whereas its inhibition of platelet-derived growth factor-induced VSMCs growth was mediated by activation of AMP-activated protein kinase/p53/p21Cip1 signaling and inactivation of Ras/ Rac1/Cyclin D/Cdks pathways [17] .
Several potential mechanisms underlying this antiproliferation/cytotoxicity have been proposed. Sethi [97] suggested that the antileukemic activity of the protoberberine alkaloids (including berberine) might be because of its inhibition of reverse transcriptase activity, which interferes with DNA synthesis. Inhibition of DNA, RNA, proteins, and lipids biosyntheses, as well as the oxidation of glucose might also contribute to this [27, 98] . In the human myeloma cell line RPMI-8226, the cytotoxic effect may be partial because of its direct blockade of voltage-dependent and Ca 2 + -dependent K + channels [88] . However, the most widely investigated mechanism involved is its role in cell cycle arrest, which has been studied by many groups in tumor and nontumor cells but with controversial results. Berberine induces G 2 /M phase arrest in nontumor Balb/c 3T3 cells [96] , which is also observed in human gastric carcinoma SNU-5 cell line [70] , leukemia cells [99] . Berberine also induces G 1 -phase cell cycle arrest in human epidermoid carcinoma A431 cells [22] , human HSC-3 oral cancer cells [100] , T98G cells [101] , murine leukemia L1210 cell lines [68] . However, in U937 and B16 cells, berberine shows no effect on cell cycle profile [23, 69] . It is also interesting to note that berberine induces G 1 -phase cell cycle arrest in human prostate carcinoma cell lines DU145, but results in a significant accumulation of cells in the G 2 -M phase in human prostate carcinoma cell lines, LNCaP and PC-3, and shows no effect on non-neoplastic human prostate epithelial cell line PWR-1E [61] . In addition, berberine exhibits protective effects against G 0 /G 1 phase arrest induced by SIN-1 in porcine kidney cell line LLC-PK1 [102] . The different concentrations used in different studies may account for the conflicting information in the literature, as berberine at low doses (12.5-50 mmol/l) is concentrated in mitochondria and promotes G 1 arrest, whereas higher doses (over 50 mmol/l) result in cytoplasmic and nuclear accumulation and G 2 arrest [29] . In fact, as early as 1996, berberine was found mainly in cytoplasm during berberine-induced (100 mg/ml) cell cycle G 2 /M arrest, whereas it was highly concentrated in nuclei in the induction of apoptosis under high dose (200 mg/ml) [96] . In addition, different cell lines exhibit significantly different sensitivities to this alkaloid, as discussed above.
Berberine-induced G 1 cell cycle arrest is mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6, and cyclins D1, D2, and E, and enhanced binding of Cdki-Cdk [22, 61, 101] . The G 2 /M cell cycle arrest induced by berberine might be mediated by suppression of the cyclin B1 expression, inhibition of Cdc2 kinase activity, and together with increased Wee1 expression through upregulation of p53 gene [70, 99, 103] . Berberine exhibits cyclin E inhibitory effect in human glioblastoma T98G cells, human prostate carcinoma DU145 cells, and human epidermoid carcinoma A431 cells [22, 61, 101] , whereas Huanglian extract (50% is berberine) does not suppress the protein expression of cyclins A or E in human gastric cancer cell line MKN-74 K562, U937 P3H1, Raji 14.1 ± 1.0 mg/ml (48 h), 9.0 ± 2.4 mg/ml (48 h), 7.9 ± 1.9 mg/ml (48 h), 0.6 ± 0. [103]. Besides the cell differences, the concentration of berberine might account a lot for this inconsistence, as the highest concentration in latter studies is only 10 mg/ml of Huanglian extract (approximately 15 mmol/l berberine), which is much lower than that of the former study. The effects of berberine on the cell cycle are shown in Fig. 2 .
Induction of apoptosis
Many potential cancer-protective agents can be broadly categorized as blocking agents, which impede the initiation stage, or suppressing agents, which arrest the promotion and progression of tumor, presumably by affecting or disturbing crucial factors that control cell proliferation, differentiation, or apoptosis [104] . Recent detailed knowledge on molecular carcinogenesis provided the potential for therapeutic intervention in cancer by specifically targeting and sensitizing cancer cells to apoptosis [105] . [52] , SW620 cells [104] , and SMMC-7721 cells [71] . Its roles in apoptosis are described below.
Alteration of proapoptotic and antiapoptotic gene expression
As is well known, Fas (APO-1/CD95) is a prototypic death receptor expressed on the surface of a number of cell types, which triggers apoptosis by binding its ligand FasL. Berberine treatment could not only dose-dependently and time-dependently increase Fas protein expression, but also induce FasL expression in tumor cell lines [104, 108] . Furthermore, berberine upregulates the proapoptotic gene p53 protein expression and activates its phosphorylation in vitro [17, 70] , which might also account for the induction of activating transcription factor 3 in human colorectal cancer cells [109] and the inhibition of platelet-derived growth factor-induced VSMCs growth [17] . Besides, p53 also cooperated in berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo [18] . More recently, several studies have shown that berberine induces cell cycle arrest and apoptosis of human osteosarcoma cells [35] , human neuroblastoma cells [110] , and prostate cancer cells [111] in a p53-dependent manner. Berberine increases Bax, another Effects of berberine on cell cycle. In tumor cells, berberine at low doses promotes G 1 arrest, whereas at higher doses, results in cytoplasmic and nuclear berberine accumulation, and G 2 arrest. BBR, berberine.
proapoptotic gene protein expression in cancer cells [22, 61, 70, 101, 107] . Meanwhile, the antiapoptotic Bcl-2 family genes, including Bcl-2, Bid, Bcl-xL, and BID, were significantly decreased [22, 61, 70, 101, 104, 108] and the ratio of Bax/Bcl-2 protein expression was elevated [101, 112] . The alteration of berberine on proapoptotic and antiapoptotic gene expression might be partly mediated by the generation of reactive oxygen species (ROS) and the activation of multiple signaling pathways, such as the JNK/p38 MAPK signaling pathway [104] , protein kinase C (PKC), ERK (extracellular signal-regulated kinase), and glycogen synthase kinase-3b [109] , etc.
Role of reactive oxygen species ROS are involved in various biological effects, such as cell activation, proliferation, survival, and apoptosis, mediated by many signaling pathways, such as MAPK, ERK1/2, JNK, NF-kB, Akt, caspases, and calcium [113] . Berberine showed inhibitory effects on lipoxygenase [114] and xanthine oxidase [60] , two important ROS-derived sources, suggesting its antioxidative potentials. Recent studies have shown that berberine could prevent Cu 2 + -induced LDL oxidation and protect oxidized LDL-induced cellular dysfunction [115] . In rat mesangial cells, berberine also significantly increased superoxide dismutase activity and decreased superoxide anion and malondialdehyde (MDA) formation [116] . In cultured rabbit corpus cavernosum smooth muscle cells, berberine inhibits the damaging effects of H 2 O 2 , with increased cell viability, NO production, superoxide dismutase activity, and decreased lactic acid dehydrogenase release and MDA content [117] . These in-vitro antioxidative results were further verified by some in-vivo studies [84, 118, 119] . However, in cell-free system, berberine (1 mmol/l) shows only moderate OH K -scavenging activity (23%), which is much less than that of berberrubine (85%) and coptisine (79%) [120] . However, some investigations have shown that berberine induces ROS formation, which might play an important role in berberine-induced apoptosis [69, 70, 104, 121] . (i) Berberine treatment increases intracellular ROS production in multiple tumor cell lines [29, 69, 70, 90, 100, 104, 112, 121] , which might be mediated by enhancement of xanthine oxidase activity and inhibition of respiratory chain complex I in mitochondria [90, 121] . Berberine treatment increases ROS generation in prostate cancer cells but not in normal prostate epithelial cells [121] , which might partly contribute to explaining the antioxidative effect of berberine in normal cells, as discussed above. Another possibility is that, at lower concentrations, prooxidant action through inhibition of complex I in mitochondria outweighs the antioxidative activity, whereas at higher concentrations, the antioxidative activity prevails over the prooxidant effect [90] . However, the autofluorescence might be neglected by some researchers, as berberine shows intensive fluorescence and its excitation and emission wavelengths are very close to the commonly used ROS probe, such as dichlorodihydrofluorescein diacetate (DCFH 2 -DA) (excitation/emission 488/ 525 nm). (ii) Pretreatment of N-acetyl-L-cysteine (NAC), a well-known antioxidant, significantly decreases berberineinduced ROS production and prevents berberine-induced apoptosis [104, 121] . (iii) NAC administration prevents berberine-induced release of cytochrome c and Smac/ DIABLO into the cytosol and reversed berberine-induced apoptosis effects through the inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression [104, 121] .
Effect on mitochondrial transmembrane potential (Dcm), cytochrome c release, and caspase activation It is widely accepted that mitochondria are central regulators of intrinsic apoptosis pathways, and alterations in mitochondrial structure and function play an important role in apoptosis. Cytochrome c release from mitochondria is a key step in the apoptosis induced by many death stimuli, whereas the caspase family members are central initiators and executioners of apoptosis.
Changes in the mitochondrial membrane potential (Dcm) have been linked to the initiation and activation of the apoptotic cascade. The fall or loss of Dcm was observed after berberine treatment in tumor cell lines, such as HepG2, SNU-5, T98G, A431, human prostate carcinoma cells, and U937 by JC-1, DiOC6, or rhodamine 123 staining [22, 69, 70, 101, 108, 121] , and in isolated rat liver mitochondria [90] . This was followed by increased cytochrome c release from mitochondria [22, 61, 108, 121] . It is certain that caspases 9, 3, and poly(ADP-ribose) polymerase are involved in berberine-induced apoptosis [22, 61, 69, 101] , whereas the activation of caspase 8 is still controversial [69, 104, 108] . In addition, berberine also remarkably downregulates the caspase inhibitor c-IAP1 protein expression in tumor cells [104] .
Effect on NF-jB activation
Berberine inhibits NF-kB activation induced by various inflammatory agents and carcinogens, such as TNF-a, PMA, okadaic acid (OA), and cigarette smoke condensate, which is mediated through the inhibition of phosphorylation and degradation of IKBa by the inhibition of IKB kinase activation, leading to the suppression of phosphorylation and nuclear translocation of p65 and finally to inhibition of NF-kB reporter activity. This resulted in the deceased expression of NF-kB-regulated gene products involved in antiapoptosis (Bcl-xL, survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (COX-2), and invasion (MMP-9) [21] . Its effect on NF-kB is nonspecific for tumor cells, which is also observed in SW620 colonic carcinoma cells [104] , keratinocytes [122] , lung epithelial cells (A-549), and fibroblasts (HFL1) [123] . However, the potential mechanisms underlying this inhibition might be different between tumor cells and nontumor cells. Berberineinhibited NF-kB activation in tumor cells is mediated by its time-dependent phosphorylation of JNK and p38 MAPK and inactivation of ERK [104] , whereas in nontumor cells this might be through suppression of Akt activation but not p38 MAPK [124] . The effect of berberine on tumor cell apoptosis is as shown in Fig. 3 .
Effect on tumor metastasis
In confrontation cultures consisting of embryoid bodies and multicellular DU-145 prostate tumor spheroids, berberine significantly inhibits MMPs, including MMP-1, MMP-2, MMP-9 protein expression and angiogenesis [125] , which is also observed in SNU-5, HL-60, and WEHI-3 cells [76, 127] . Furthermore, berberine also decreased basal and UV-induced MMP-1 and TPAinduced MMP-9 expression and activity in human dermal fibroblasts and normal human keratinocytes, respectively [76, 127] . This MMP inhibition is partly mediated by decreased intracellular ROS levels, as free radical scavengers, such as vitamin E, also shows similar results [107, 126] . In human lung cancer A549 cells, berberine inhibits MMP-2 expression by regulating the tissue inhibitor of metalloproteinase-2 [85] . In rat C6 glioma cells and U-87 human malignant glioma cells, berberine significantly decreases the activation of PKCa and PKCe, and leads to actin cytoskeleton rearrangements. The levels of two downstream transcription factors, myc and jun, and MMP-1 and MMP-2 are also significantly reduced [74] . The suppression of MMPs partly contributes to the inhibitory effect on the motility and invasion ability of the tumor cells [86] . However, berberine shows no inhibitory effect on the phosphorylation of Akt and enzymatic activity of MMP-2 [128] . A recent study has shown that berberine inhibits migration and invasion of human SCC-4 tongue squamous carcinoma cells, which is mediated by the p-JNK, p-ERK, p-p38, IkK, and NF-kB signaling pathways resulting in inhibition of u-PA, MMP-2 and MMP-9 [129] . Effect of berberine on apoptosis. Three signaling pathways might be involved in berberine-induced apoptosis: (i) Berberine could accumulate in mitochondria, increase mitochondria ROS formation, and affect mitochondrial transmembrane potential (Dcm), which result in the cytochrome c release and activation of caspases 9 and 3. (ii) Berberine activates Fas/FasL death receptor pathway to induce apoptosis. (iii) Berberine induced JNK and p38 MAPK phosphorylation mediated by ROS, which might lead to the suppression of nuclear factor-kB (NF-kB) activation. Furthermore, berberine increases proapoptotic gene, such as Bax, and decreases antiapoptotic gene, such as Bcl-2, Bcl-xL, Bid, Survivin, IAP1, IAP2, and cFLIP. BBR, berberine; ROS, reactive oxygen species.
NM23-H1 and SDF-1 are candidate genes involved in the mobility and migration of tumor cells. Berberine could substantially increase the expression of NM23-H1 and reduce SDF-1 protein level, which results in decreased 5-8F cell motility and leukemic stem cells migration [78, 130] .
Berberine directly inhibits human umbilical vein endothelial cells tube formation in vitro. Migration and modified confrontation culture experiments showed that berberine inhibits the capacity of hypoxic SC-M1 cells to stimulate human umbilical vein endothelial cells migration, which is because of its regulation on vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1a, two key factors in mediating tumor angiogenesis. Berberine does not downregulate HIF-1a mRNA but destabilized HIF-1a protein through proteolysis, which abrogates the accumulation of HIF-1 and the trans-activation of VEGF gene and subsequently abolishes hypoxia-induced VEGF expression [73] .
In vitro, berberine exerts a dose-dependent and timedependent inhibitory effect on the motility and invasion ability of highly metastatic A549 cells under noncytotoxic concentrations. This results from its inhibition of u-PA and MMP-2 expression through regulating the urokinase-plasminogen activator inhibitor and the tissue inhibitor of metalloproteinase-2, respectively, which is meditated by upstream mediators of the effect involved c-jun, c-fos, and NF-kB [85] . In vivo, oral administration of berberine for 14 days significantly inhibits the spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma into the lung parenchyma in a dose-dependent manner, but does not affect the tumor growth at the implantation site of the lung. These antimetastatic properties are mediated through repression of AP-1 activity by suppressing the expression of u-PA [86] , whose overexpression is correlated with lymphatic metastasis of lung cancer [131, 132] .
Application in combined medication
In GBM cells, treatment with a nontoxic dose of berberine renders GBM cells more sensitive than vehicle-treated control cells to X-rays (radiosensitization), which is not observed in primary human glial cultures, suggesting that berberine could be integrated with postoperative radiotherapy to selectively promote residual GBM tumor cell death [79] . As 2 O 3 -induced inhibition of glioma cell growth, reduction in motility and invasion are significantly enhanced by berberine cotreatment [74] . More recently, a study indicated that berberine and Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer MCF-7 cells through downregulating the expression of EGFR, HER2, Bcl-2, and COX-2, and upregulating IFN-b and p21 [53] . These studies suggest the potential of berberine in the combined medication in tumor chemotherapy.
Improvement of multidrug resistance
The ATP-binding cassette (ABC)-superfamily multidrug efflux pumps are known to be responsible for chemoresistance: P-glycoprotein (ABCB1), MRP1 (ABCC1), and ABCG2 (breast cancer resistance protein). These transporters play an important role in normal physiology by protecting tissues from toxic xenobiotics and endogenous metabolites [133] . ABCG2 has been identified as a multidrug transporter that confers resistance on tumor cells [134] . The ABC proteins of the MDR-type meditate berberine uptake in cultured Coptis japonica cells [135] . Furthermore, the ABCG2 expression and the side population are decreased by berberine in MCF-7 breast cancer cells [72] .
The overexpression of human multidrug resistance (MDR1) gene coding for multidrug resistance transporter (pgp-170) has been reported in numerous solid tumors, including colon carcinoma, renal carcinoma, hepatoma, and pancreatic carcinoma. Berberine treatment could upregulate the pgp-170 expression in oral (KB,OC2), gastric (SC-M1,NUGC-3), colon (COLO205,CT26), and HepG2, Hep3B, HA22T/VGH cancer cells [136, 137] . Furthermore, paclitaxel induced dose-dependent cytotoxicity, apoptosis and/or G 2 /M arrest in OC2, SCM1, and COLO205 cells is blocked by berberine pretreatment, which might be mediated by its modulation of pgp-170 expression and function in these cells [136] .
In-vivo anticancer activities
One of the earlier studies suggested that cytostatic activity of berberine against Ehrlich ascites and a lymphomatous ascites tumor is manifested only in culture and not when the tumors are growing in mice [138] . Berberine also exerts an inhibitory action on the growth of S180 cells in culture but when given to tumorbearing mice by daily injections, there is no prolongation of survival. Rather, the life span decreases with increasing doses [27] .
However, later studies have shown that berberine exhibits significant anticancer effects in vivo. In Dalton's lymphoma ascites tumor cells-bearing mice, berberine hydrochloride treatment remarkably increases life span and intraperitoneal administration is more effective than oral administration [95] . Berberine and tetrahydroberberine derivatives show no anticancer activity, but berberine, berberrubine, and the ester derivatives of berberrubine exhibit a strong activity against sarcoma-180 ascites [139] . Berberine sulfate inhibits the effects of the tumor promoters 12-O-tetradecanoylphorbol-13-acetate, teleocidin, and markedly suppresses the promoting effect of teleocidin on skin tumor formation in mice initiated with 7,12-dimethylbenz[a]anthracene [140] . 20-Methylcholanthrene or N-nitrosodiethyl-amine-induced carcinogenesis is also significantly suppressed by berberine hydrochloride in a dose-dependent manner in small animals, indicating that berberine offers protection against chemical carcinogenesis [141] . In animal studies, berberine also potentiates the anticancer activity of carmustine, cyclophosphamide, or Alstonia scholaris extract when used in combination [95, 142, 143] . Furthermore, this synergistic effect is also observed when berberine and irradiation are applied in combination to treat both in-vivo and in-vitro models of lung cancer [144] . Berberine inhibits azoxymethane (AOM)-induced aberrant crypt foci (ACF) formation and putative preneoplastic lesions of the colon in male F344 rats, which is because of its inhibition of COX-2 activity [145] . Furthermore, berberine administration also improves AOM-induced lipid peroxidation, protein-bound carbohydrates, and antioxidative status in rats [146] . In addition, Coptidis rhizoma supplement significantly attenuates weight loss of nude mice carrying a human esophageal cancer cell line YES-2 without a change in food or water intake, and its major component berberine dose-dependently inhibits secretion of IL-6 by YES-2 cells in vitro [147] . The same group reported similar results in syngeneic mice bearing colon 26/clone 20 carcinoma cells [148] . In a CC-4 tumor cell-implanted murine xenograft model, berberine treatment results in a reduction in both tumor incidence and tumor size [149] .
Furthermore, in Friend murine leukemia virus (FMuLv)-induced erythroleukemia in BALB/c mice, berberine elevates the life span of leukemia-harboring animals by more than 60 days, which might be partly because of the decreased expression of Bcl-2, Raf-1, Erk-1 IFN-g receptor and erythropoietin and increased expression of p53 [150] .
However, there is observation that low dose of berberine (1 mg/kg) might stimulate tumor mass, although higher doses (5 and 10 mg/kg) significantly reduce the tumor volume and tumor weight [77] . It is also interesting to note that oral administration of berberine significantly inhibits the spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma into the lung parenchyma in a dose-dependent manner, but does not affect the tumor growth at the implantation site of the lung [86] .
Conclusion
Decades of basic research provide evidence that berberine has anticancer potential, which happens at different layers and different stages of tumorigenesis. However, the inconsistence of its anticancer activities in vivo needs further systemic study to evaluate. Berberine has been widely used to treat gastroenteritis and diarrhea patients in the Chinese population for a long time and side effects can result from high dosages and may include gastrointestinal discomfort, dyspnea, lowered blood pressure, flu-like symptoms, and cardiac damage [3] . These accumulated data may be helpful for its future clinical trials for cancer chemotherapy.
